[go: up one dir, main page]

MX2024004551A - Inhibidores de la replicacion del virus de inmunodeficiencia humana. - Google Patents

Inhibidores de la replicacion del virus de inmunodeficiencia humana.

Info

Publication number
MX2024004551A
MX2024004551A MX2024004551A MX2024004551A MX2024004551A MX 2024004551 A MX2024004551 A MX 2024004551A MX 2024004551 A MX2024004551 A MX 2024004551A MX 2024004551 A MX2024004551 A MX 2024004551A MX 2024004551 A MX2024004551 A MX 2024004551A
Authority
MX
Mexico
Prior art keywords
inhibitors
immunodeficiency virus
human immunodeficiency
virus replication
formula
Prior art date
Application number
MX2024004551A
Other languages
English (en)
Inventor
Gautam Dalwadi
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MX2024004551A publication Critical patent/MX2024004551A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se expone una composición farmacéutica que comprende el compuesto de la Fórmula Ia, o la Fórmula Ib, o una sal farmacéuticamente aceptable del mismo: (ver Fórmulas).
MX2024004551A 2021-10-13 2022-10-12 Inhibidores de la replicacion del virus de inmunodeficiencia humana. MX2024004551A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163255056P 2021-10-13 2021-10-13
US202163257212P 2021-10-19 2021-10-19
PCT/IB2022/059780 WO2023062559A1 (en) 2021-10-13 2022-10-12 Inhibitors of human immunodeficiency virus replication

Publications (1)

Publication Number Publication Date
MX2024004551A true MX2024004551A (es) 2024-06-26

Family

ID=84044276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024004551A MX2024004551A (es) 2021-10-13 2022-10-12 Inhibidores de la replicacion del virus de inmunodeficiencia humana.

Country Status (10)

Country Link
US (1) US20240423985A1 (es)
EP (1) EP4415685A1 (es)
JP (1) JP2024535596A (es)
KR (1) KR20240074850A (es)
AU (1) AU2022362855B2 (es)
CA (1) CA3234219A1 (es)
CL (1) CL2024001073A1 (es)
IL (1) IL311982A (es)
MX (1) MX2024004551A (es)
WO (1) WO2023062559A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3347352T3 (pl) * 2016-08-19 2019-12-31 Gilead Sciences, Inc. Związki terapeutyczne użyteczne do profilaktycznego lub terapeutycznego leczenia zakażenia wirusem HIV
AR112413A1 (es) * 2017-08-17 2019-10-23 Gilead Sciences Inc Formas sólidas de un inhibidor de la cápside del vih
KR20230141905A (ko) * 2018-07-16 2023-10-10 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
BR112021007362A2 (pt) * 2018-10-24 2021-07-20 VIIV Healthcare UK (No.5) Limited inibidores da replicação do vírus da imunodeficiência humana
HUE065762T2 (hu) * 2019-06-19 2024-06-28 Viiv Healthcare Uk No 5 Ltd Pirido[2,3-d]pirimidin-származékok mint a humán immunhiányos vírus replikációjának gátlói
CN115397424A (zh) * 2020-04-15 2022-11-25 Viiv保健英国第五有限公司 人类免疫缺陷病毒复制的抑制剂

Also Published As

Publication number Publication date
CA3234219A1 (en) 2023-04-20
US20240423985A1 (en) 2024-12-26
CL2024001073A1 (es) 2024-10-04
AU2022362855B2 (en) 2025-08-14
WO2023062559A1 (en) 2023-04-20
IL311982A (en) 2024-06-01
EP4415685A1 (en) 2024-08-21
KR20240074850A (ko) 2024-05-28
AU2022362855A1 (en) 2024-05-02
JP2024535596A (ja) 2024-09-30

Similar Documents

Publication Publication Date Title
ECSP22071009A (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
CL2022002817A1 (es) Inhibidores de replicación del virus de inmunodeficiencia humana
CL2024000593A1 (es) Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento...
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2022001529A1 (es) Nuevos derivados de metilquinazolinona
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA202190854A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
AR111820A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
ECSP22032016A (es) Inhibidor de irak y método de preparación para el mismo y uso del mismo
AR131639A1 (es) Inhibidores de kif18a y usos de los mismos
CO2024003094A2 (es) Compuesto imidazocíclico y aplicación del mismo
AR128066A1 (es) Compuesto heterocíclico de pirimidina y método de preparación y uso médico de los mismos
CL2023000387A1 (es) Derivados de dioxoloisoquinolinona novedosos y uso de los mismos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
MX2024004551A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana.
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)
CL2022002490A1 (es) Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead
AR130303A1 (es) Compuestos de pirazolilsulfonamida y su uso terapéutico
AR132166A1 (es) Inhibidores de inflamasoma nlrp3 y usos de los mismos
AR131842A1 (es) Métodos para tratar gliomas
MX2024014557A (es) Derivados de piperazina útiles en la terapia contra el vih
AR129588A1 (es) Inhibidores de kras
AR133855A1 (es) Compuestos de amina sustituida, composiciones y métodos de uso